Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000050250 | SCV004559563 | likely benign | Pulmonary hypertension, primary, 2 | 2023-06-07 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000050250 | SCV000082859 | pathogenic | Pulmonary hypertension, primary, 2 | 2011-12-01 | no assertion criteria provided | literature only | |
Prevention |
RCV003982871 | SCV004797050 | uncertain significance | SMAD9-related disorder | 2024-01-15 | no assertion criteria provided | clinical testing | The SMAD9 c.127A>G variant is predicted to result in the amino acid substitution p.Lys43Glu. This variant has been reported in an individual with pulmonary arterial hypertension and functional studies were inconclusive as to the variant's effect on protein function (Nasim et al. 2011. PubMed ID: 21898662). This variant is reported in 0.15% of alleles in individuals of East Asian descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |